Abstract
While chemo- and radiotherapy is far developed and successfully employed by default for cancer treatment, severe side effects point to the urgent need for more specific therapies based on the molecular mechanisms of this disease. Strategies to specifically inhibit signaling pathways that are known to force proliferation, prevent apoptosis or promote angiogenesis are expected to have a substantial impact on the future direction taken in cancer therapy. The Janus Kinase (JAK) / Signal transducer and activator of transcription (STAT) pathway is one major signaling pathway converting the signal of cytokines, growth factors and hormones into gene expression programs regulating essential cellular functions like proliferation, differentiation and survival. The suppressors of cytokine signaling (SOCS) as well as phosphatases normally tightly regulate the JAK/STAT pathway. Frequently, however this pathway is constitutively activated in a wide variety of human malignancies and substantially contributes to carcinogenesis. Consequently, new strategies for targeting the JAK/STAT pathway have been developed. This review discusses the biology of the JAK/STAT signaling pathway, which offers several molecular strategies for therapeutic interruption.
Keywords: STAT, JAK, cancer, cytokine, SOCS, signaling, inhibitors
Current Signal Transduction Therapy
Title: Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy
Volume: 1 Issue: 3
Author(s): Edith Pfitzner, Frank Nonnenmacher and Daniela Baus
Affiliation:
Keywords: STAT, JAK, cancer, cytokine, SOCS, signaling, inhibitors
Abstract: While chemo- and radiotherapy is far developed and successfully employed by default for cancer treatment, severe side effects point to the urgent need for more specific therapies based on the molecular mechanisms of this disease. Strategies to specifically inhibit signaling pathways that are known to force proliferation, prevent apoptosis or promote angiogenesis are expected to have a substantial impact on the future direction taken in cancer therapy. The Janus Kinase (JAK) / Signal transducer and activator of transcription (STAT) pathway is one major signaling pathway converting the signal of cytokines, growth factors and hormones into gene expression programs regulating essential cellular functions like proliferation, differentiation and survival. The suppressors of cytokine signaling (SOCS) as well as phosphatases normally tightly regulate the JAK/STAT pathway. Frequently, however this pathway is constitutively activated in a wide variety of human malignancies and substantially contributes to carcinogenesis. Consequently, new strategies for targeting the JAK/STAT pathway have been developed. This review discusses the biology of the JAK/STAT signaling pathway, which offers several molecular strategies for therapeutic interruption.
Export Options
About this article
Cite this article as:
Pfitzner Edith, Nonnenmacher Frank and Baus Daniela, Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy, Current Signal Transduction Therapy 2006; 1 (3) . https://dx.doi.org/10.2174/157436206778226914
DOI https://dx.doi.org/10.2174/157436206778226914 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Protein Targeted Therapy of Metastatic Melanoma
Current Pharmaceutical Design Pharmacokinetics-Guided Dosing of 5-Fluorouracil for Precision Cancer Treatment: A Focus on Colorectal Carcinoma
Applied Clinical Research, Clinical Trials and Regulatory Affairs Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine Targeted Cancer Therapy; Nanotechnology Approaches for Overcoming Drug Resistance
Current Medicinal Chemistry NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in Metabolomics
Current Metabolomics Skin Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Lesson Learned from Nature for the Development of Novel Anti-Cancer Agents: Implication of Isoflavone, Curcumin, and their Synthetic Analogs
Current Pharmaceutical Design Pharmacological Control of Autophagy: Therapeutic Perspectives in Inflammatory Bowel Disease and Colorectal Cancer
Current Pharmaceutical Design Defining the Cough Spectrum and Reviewing the Evidence for Treating Non-Specific Cough in Children
Current Pediatric Reviews Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Identification of KEY lncRNAs and mRNAs Associated with Oral Squamous Cell Carcinoma Progression
Current Bioinformatics Recent Developments in Boron Neutron Capture Therapy (BNCT) Driven by Nanotechnology
Current Chemical Biology Editorial [ The Role of Epidermal Growth Factor Receptor (EGFR) Targeting Drugs in the Treatment of Cancer Guest Editor: Fortunato Ciardiello ]
Current Cancer Therapy Reviews Update on Laser Photochemotherapy: An Alternative for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry CD40L - A Multipotent Molecule for Tumor Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Selections
Recent Patents on Biomarkers Inactivation of Parathyroid Hormone: Perspectives of Drug Discovery to Combating Hyperparathyroidism
Current Molecular Pharmacology Synthesis, Photophysical and Photochemical Aspects of Phthalocyanines for Photodynamic Therapy
Current Organic Chemistry 89Zr Radiochemistry for Positron Emission Tomography
Medicinal Chemistry